LU87411A1 - Compositions aqueuses contenant un derive de l'acide piperidinylcyclopentylheptenoique - Google Patents

Compositions aqueuses contenant un derive de l'acide piperidinylcyclopentylheptenoique Download PDF

Info

Publication number: LU87411A1
Authority: LU; Luxembourg
Prior art keywords: compound; cyclodextrin; hydrochloride salt; solution; composition according
Prior art date: 1987-12-22

Application number

LU87411A

Other languages

English (en)

French (fr)

Inventor

Finch Harry

Phillips Anthony John

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-22

Filing date

1988-12-21

Publication date

1989-07-07

1987-12-22 Priority claimed from GB878729823A external-priority patent/GB8729823D0/en

1988-02-25 Priority claimed from GB888804422A external-priority patent/GB8804422D0/en

1988-12-21 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1989-07-07 Publication of LU87411A1 publication Critical patent/LU87411A1/fr

Links

239000000203 mixture Substances 0.000 title claims description 53
JAIYKLJZOBJGSG-UHFFFAOYSA-N 2-cyclopentyl-3-piperidin-1-ylhept-2-enoic acid Chemical class C1CCCC1C(C(O)=O)=C(CCCC)N1CCCCC1 JAIYKLJZOBJGSG-UHFFFAOYSA-N 0.000 title description 2
229940126062 Compound A Drugs 0.000 claims description 63
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 63
229920000858 Cyclodextrin Polymers 0.000 claims description 45
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 40
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 31
229960004853 betadex Drugs 0.000 claims description 31
239000001116 FEMA 4028 Substances 0.000 claims description 27
235000011175 beta-cyclodextrine Nutrition 0.000 claims description 27
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 27
238000002347 injection Methods 0.000 claims description 26
239000007924 injection Substances 0.000 claims description 26
-1 salt hydrochloride Chemical class 0.000 claims description 9
238000001802 infusion Methods 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 5
239000004305 biphenyl Substances 0.000 claims description 4
239000000470 constituent Substances 0.000 claims description 4
239000012458 free base Substances 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
239000000243 solution Substances 0.000 description 61
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
229930195725 Mannitol Natural products 0.000 description 8
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 8
229940080345 gamma-cyclodextrin Drugs 0.000 description 8
239000000594 mannitol Substances 0.000 description 8
235000010355 mannitol Nutrition 0.000 description 8
239000002585 base Substances 0.000 description 7
229940097362 cyclodextrins Drugs 0.000 description 7
239000007787 solid Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 5
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 4
229940043377 alpha-cyclodextrin Drugs 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000011521 glass Substances 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000011321 prophylaxis Methods 0.000 description 4
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 4
238000011282 treatment Methods 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
239000002775 capsule Substances 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
235000019980 sodium acid phosphate Nutrition 0.000 description 3
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
239000000725 suspension Substances 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000008469 Peptic Ulcer Diseases 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
235000019800 disodium phosphate Nutrition 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000007429 general method Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
125000002768 hydroxyalkyl group Chemical group 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010007556 Cardiac failure acute Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
208000035965 Postoperative Complications Diseases 0.000 description 1
206010050902 Postoperative thrombosis Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000008364 bulk solution Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
229940126142 compound 16 Drugs 0.000 description 1
238000011109 contamination Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000009877 rendering Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 1
IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
239000002396 thromboxane receptor blocking agent Substances 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nanotechnology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

LU87411A 1987-12-22 1988-12-21 Compositions aqueuses contenant un derive de l'acide piperidinylcyclopentylheptenoique LU87411A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB8729823		1987-12-22
GB878729823A GB8729823D0 (en)	1987-12-22	1987-12-22	Complexes
GB888804422A GB8804422D0 (en)	1988-02-25	1988-02-25	Complexes
GB8804422		1988-02-25

Publications (1)

Publication Number	Publication Date
LU87411A1 true LU87411A1 (fr)	1989-07-07

Family

ID=26293226

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU87411A LU87411A1 (fr)	1987-12-22	1988-12-21	Compositions aqueuses contenant un derive de l'acide piperidinylcyclopentylheptenoique

Country Status (29)

Country	Link
JP (1)	JPH02210A (sv)
KR (1)	KR890009402A (sv)
CN (1)	CN1034132A (sv)
AT (1)	AT395943B (sv)
AU (1)	AU615245B2 (sv)
BE (1)	BE1001704A3 (sv)
CA (1)	CA1328078C (sv)
CH (1)	CH676665A5 (sv)
DE (1)	DE3843059A1 (sv)
DK (1)	DK712888A (sv)
ES (1)	ES2011727A6 (sv)
FI (1)	FI885920A (sv)
FR (1)	FR2624731B1 (sv)
GB (1)	GB2211737B (sv)
GR (1)	GR880100854A (sv)
HU (1)	HU204700B (sv)
IE (1)	IE61995B1 (sv)
IL (1)	IL88764A0 (sv)
IT (1)	IT1224835B (sv)
LU (1)	LU87411A1 (sv)
MY (1)	MY103952A (sv)
NL (1)	NL8803126A (sv)
NO (1)	NO885689L (sv)
NZ (1)	NZ227446A (sv)
PH (1)	PH24982A (sv)
PL (1)	PL276595A1 (sv)
PT (1)	PT89301B (sv)
SE (1)	SE502288C2 (sv)
ZW (1)	ZW18088A1 (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8814725D0 (en) *	1988-06-21	1988-07-27	Glaxo Group Ltd	Medicaments
AU616571B2 (en) *	1988-10-28	1991-10-31	Shiseido Company Ltd.	Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
IT1269578B (it) *	1994-04-22	1997-04-08	Chiesi Farma Spa	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
KR100825736B1 (ko) *	2005-12-07	2008-04-29	한국전자통신연구원	무선 ｘｍｌ 전자 서명 서비스 제공 장치 및 그 방법
KR100832740B1 (ko) *	2007-01-17	2008-05-27	한국과학기술원	분지쇄 아미노산 생성능이 개선된 변이 미생물 및 이를이용한 분지쇄 아미노산의 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS503362B1 (sv) *	1970-06-10	1975-02-04
JPS5443569B2 (sv) *	1972-07-05	1979-12-20
HU181703B (en) *	1980-05-09	1983-11-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
JPS57183772A (en) *	1981-04-29	1982-11-12	Glaxo Group Ltd	Aminocyclopentanol acids and esters, manufacture and medicinal composition
JPS58116423A (ja) *	1981-12-28	1983-07-11	Sumitomo Chem Co Ltd	メタノプロスタサイクリン製剤組成物
JPS58192821A (ja) *	1982-04-30	1983-11-10	Dainippon Pharmaceut Co Ltd	脳神経細胞の酸素欠乏性疾患の治療剤
JPS5946228A (ja) *	1982-09-08	1984-03-15	Zeria Shinyaku Kogyo Kk	生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法
JPS5973576A (ja) *	1982-09-16	1984-04-25	グラクソ・グル−プ・リミテツド	ピペリジニルシクロペンタノ−ルヘプテン酸塩
GB2127406B (en) *	1982-09-16	1986-03-05	Glaxo Group Ltd	Piperidinlycyclopentanolheptenoic acid salt
DE3346123A1 (de) *	1983-12-21	1985-06-27	Janssen Pharmaceutica, N.V., Beerse	Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60150039A (ja) *	1984-01-17	1985-08-07	Minolta Camera Co Ltd	水陸両用固定焦点カメラ
DE3504044A1 (de) *	1985-02-04	1986-08-07	Schering AG, Berlin und Bergkamen, 1000 Berlin	9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
JPS6327440A (ja) *	1986-07-18	1988-02-05	Sanraku Inc	グルコシル化分岐シクロデキストリン含有組成物

1988
- 1988-12-21 HU HU886537A patent/HU204700B/hu not_active IP Right Cessation
- 1988-12-21 LU LU87411A patent/LU87411A1/fr unknown
- 1988-12-21 JP JP63320759A patent/JPH02210A/ja active Pending
- 1988-12-21 DK DK712888A patent/DK712888A/da not_active Application Discontinuation
- 1988-12-21 AU AU27356/88A patent/AU615245B2/en not_active Ceased
- 1988-12-21 BE BE8801423A patent/BE1001704A3/fr not_active IP Right Cessation
- 1988-12-21 AT AT0313088A patent/AT395943B/de not_active IP Right Cessation
- 1988-12-21 ZW ZW180/88A patent/ZW18088A1/xx unknown
- 1988-12-21 DE DE3843059A patent/DE3843059A1/de not_active Ceased
- 1988-12-21 FI FI885920A patent/FI885920A/fi not_active Application Discontinuation
- 1988-12-21 PT PT89301A patent/PT89301B/pt not_active IP Right Cessation
- 1988-12-21 PH PH37963A patent/PH24982A/en unknown
- 1988-12-21 GB GB8829793A patent/GB2211737B/en not_active Expired - Fee Related
- 1988-12-21 GR GR880100854A patent/GR880100854A/el unknown
- 1988-12-21 CH CH4758/88A patent/CH676665A5/de not_active IP Right Cessation
- 1988-12-21 NZ NZ227446A patent/NZ227446A/xx unknown
- 1988-12-21 CN CN88108916A patent/CN1034132A/zh active Pending
- 1988-12-21 ES ES8803876A patent/ES2011727A6/es not_active Expired - Fee Related
- 1988-12-21 NO NO88885689A patent/NO885689L/no unknown
- 1988-12-21 FR FR8816902A patent/FR2624731B1/fr not_active Expired - Fee Related
- 1988-12-21 PL PL27659588A patent/PL276595A1/xx unknown
- 1988-12-21 IE IE382088A patent/IE61995B1/en not_active IP Right Cessation
- 1988-12-21 KR KR1019880017106A patent/KR890009402A/ko not_active Application Discontinuation
- 1988-12-21 CA CA000586606A patent/CA1328078C/en not_active Expired - Fee Related
- 1988-12-21 IT IT8848702A patent/IT1224835B/it active
- 1988-12-21 SE SE8804607A patent/SE502288C2/sv not_active IP Right Cessation
- 1988-12-21 NL NL8803126A patent/NL8803126A/nl not_active Application Discontinuation
- 1988-12-22 MY MYPI88001508A patent/MY103952A/en unknown
- 1988-12-22 IL IL88764A patent/IL88764A0/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ227446A (en)	1991-08-27
SE502288C2 (sv)	1995-09-25
SE8804607D0 (sv)	1988-12-21
AT395943B (de)	1993-04-26
SE8804607L (sv)	1989-06-23
ES2011727A6 (es)	1990-02-01
FR2624731A1 (fr)	1989-06-23
GB8829793D0 (en)	1989-02-15
IL88764A0 (en)	1989-07-31
PL276595A1 (en)	1989-08-21
BE1001704A3 (fr)	1990-02-13
IT1224835B (it)	1990-10-24
IE61995B1 (en)	1994-12-14
GB2211737B (en)	1991-12-11
AU2735688A (en)	1989-06-22
FR2624731B1 (fr)	1992-10-23
ZW18088A1 (en)	1989-07-26
FI885920A (fi)	1989-06-23
CA1328078C (en)	1994-03-29
IE883820L (en)	1989-06-22
PH24982A (en)	1990-12-26
DK712888D0 (da)	1988-12-21
NO885689L (no)	1989-06-23
HU204700B (en)	1992-02-28
NO885689D0 (no)	1988-12-21
PT89301A (pt)	1990-06-29
GB2211737A (en)	1989-07-12
JPH02210A (ja)	1990-01-05
KR890009402A (ko)	1989-08-01
ATA313088A (de)	1992-09-15
MY103952A (en)	1993-10-30
AU615245B2 (en)	1991-09-26
CH676665A5 (sv)	1991-02-28
DK712888A (da)	1989-06-23
CN1034132A (zh)	1989-07-26
PT89301B (pt)	1995-07-03
HUT50040A (en)	1989-12-28
GR880100854A (el)	1994-03-31
IT8848702A0 (it)	1988-12-21
DE3843059A1 (de)	1989-07-13
NL8803126A (nl)	1989-07-17

Publication	Publication Date	Title
EP0399903B1 (fr)	1992-12-23	Nouvelles compositions à base d'imipramine
FR2466248A1 (fr)	1981-04-10	Derives d'agents anti-inflammatoires non steroides, procede de preparation et compositions pharmaceutiques les contenant
JPH0336827B2 (sv)	1991-06-03
CZ289746B6 (cs)	2002-03-13	Ve vodě rozpustná sůl nimesulidu, způsob její přípravy, vodný roztok, jenľ ji obsahuje, kombinace zaloľené na nimesulidu a jejich pouľití
CH668594A5 (fr)	1989-01-13	Preparations parenterales de phenytoine.
EP1535916B1 (en)	2010-12-01	Inclusion complexes of butylphthalide with cyclodextrin derivatives and processes for their preparation
US4952565A (en)	1990-08-28	Inclusion complex of ibuproxam with beta-cyclodextrin, a process for preparing the same and a pharmaceutical preparation containing the same
EP1343473A1 (fr)	2003-09-17	Composition pharmaceutique de dronedarone pour administration parenterale
US20090023683A1 (en)	2009-01-22	Complexes comprising zoledronic acid and cyclodextrins
LU87411A1 (fr)	1989-07-07	Compositions aqueuses contenant un derive de l'acide piperidinylcyclopentylheptenoique
US7259153B2 (en)	2007-08-21	Drug formulation and delivery using crystalline methylated cyclodextrins
LU87102A1 (fr)	1988-08-23	Combinaison iyophilisee ou precipitee de zwitterbn de cephalosporine et de sel
CH670448A5 (sv)	1989-06-15
FR2482458A1 (fr)	1981-11-20	Compositions antitumorales a base de methanesulfon-m-anisidine
US5221695A (en)	1993-06-22	Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin
CA2039120C (fr)	2002-08-13	Complexes de l'acide tiaprofenique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs derives
LU82965A1 (fr)	1981-06-04	Nouveaux sels d'addition d'acides du 4'-(9-acridinylamino)methanesulf-m-anisidide,leur procede de production et composition pharmaceutique les contenant
MXPA04011777A (es)	2005-03-31	Composicion farmaceutica.
JPH01131202A (ja)	1989-05-24	新規な腸溶性分子カプセル
BE887220A (fr)	1981-07-23	Compositions antitumeurs
RU2803937C2 (ru)	2023-09-22	Состав для парентерального введения, содержащий сипонимод
LU83081A1 (fr)	1981-09-10	Compositions antitumeurs
BE821696A (fr)	1975-04-30	Procede de preparation d'une formulation stable contenant une prostaglandine du groupe e
KR100673558B1 (ko)	2007-01-25	사이클로덱스트린 또는 이의 유도체와 부틸프탈리드의 내포 착물, 이들의 제조 방법 및 용도
BE886413A (fr)	1981-06-01	Nouveaux sels d'addition d'acides du 4'-(9-acridinylamino) methanesulf-m-anisidide, leur procede de production et composition pharmaceutique les contenant